Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed COO
Employment agrmnt
TCR2 THERAPEUTICS INC. (TCRR) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/12/2023 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
06/01/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
06/01/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
06/01/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
06/01/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/01/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/01/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/01/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/01/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/01/2023 4 Allen Andrew R (Director) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Disposed/sold 16,800 options to buy @ $0.97, valued at $16.3k
Disposed/sold 12,100 options to buy @ $5.21, valued at $63k
Disposed/sold 12,100 options to buy @ $31.83, valued at $385.1k
Disposed/sold 5,000 options to buy @ $16.1, valued at $80.5k
Disposed/sold 6,270 options to buy @ $16.11, valued at $101k
Disposed/sold 8,072 options to buy @ $6.07, valued at $49k
06/01/2023 4 Tomasello Shawn (Director) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Disposed/sold 16,800 options to buy @ $0.97, valued at $16.3k
Disposed/sold 12,100 options to buy @ $5.21, valued at $63k
Disposed/sold 15,191 options to buy @ $26.33, valued at $400k
Disposed/sold 4,177 options to buy @ $26.33, valued at $110k
06/01/2023 4 Sullivan Eric (CFO) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Disposed/sold 40,820 options to buy @ $0.97, valued at $39.6k
Disposed/sold 250,000 options to buy @ $2.89, valued at $722.5k
Disposed/sold 6,804 restricted stock units @ $0
06/01/2023 4 Cardama Alfonso Quintas (Chief Medical Officer) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Disposed/sold 109,459 shares @ $0
Disposed/sold 70,649 options to buy @ $0.97, valued at $68.5k
Disposed/sold 31,582 options to buy @ $0.74, valued at $23.4k
Disposed/sold 42,346 options to buy @ $0.74, valued at $31.3k
Disposed/sold 90,720 options to buy @ $5.88, valued at $533.4k
Disposed/sold 114,700 options to buy @ $5.21, valued at $597.6k
Disposed/sold 11,775 restricted stock units @ $0
Disposed/sold 1,409 restricted stock units @ $0
Disposed/sold 6,489 restricted stock units @ $0
Disposed/sold 9,549 restricted stock units @ $0
06/01/2023 4 Olagunju Peter (COO) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Disposed/sold 24,092 shares @ $0
Disposed/sold 98,124 options to buy @ $0.97, valued at $95.2k
Disposed/sold 47,100 options to buy @ $5.21, valued at $245.4k
Disposed/sold 16,354 restricted stock units @ $0
Disposed/sold 62,047 restricted stock units @ $0
06/01/2023 4 Webster Stephen W (Director) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Disposed/sold 16,800 options to buy @ $0.97, valued at $16.3k
Disposed/sold 12,100 options to buy @ $31.83, valued at $385.1k
Disposed/sold 12,100 options to buy @ $5.21, valued at $63k
Disposed/sold 10,482 options to buy @ $9.54, valued at $100k
06/01/2023 4 Harrison Rosemary (Chief Business & Strategy) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Disposed/sold 76,930 options to buy @ $0.97, valued at $74.6k
Disposed/sold 12,822 restricted stock units @ $0
Disposed/sold 191,102 options to buy @ $4.04, valued at $772.1k
06/01/2023 4 Menzel Garry E (President and CEO) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Disposed/sold 132,729 shares @ $0
Disposed/sold 132,730 shares @ $0
Disposed/sold 138,871 shares @ $0
Disposed/sold 138,031 options to buy @ $0.74, valued at $102.1k
Disposed/sold 433,037 options to buy @ $5.88, valued at $2.5M
Disposed/sold 305,800 options to buy @ $5.21, valued at $1.6M
Disposed/sold 238,008 options to buy @ $0.97, valued at $230.9k
Disposed/sold 3,241 restricted stock units @ $0
Disposed/sold 15,120 restricted stock units @ $0
Disposed/sold 23,165 restricted stock units @ $0
Disposed/sold 39,681 restricted stock units @ $0
06/01/2023 4 Justice Angela (Chief People Officer) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Disposed/sold 48,745 shares @ $0
Disposed/sold 78,499 options to buy @ $0.97, valued at $76.1k
Disposed/sold 76,500 options to buy @ $5.21, valued at $398.6k
Disposed/sold 13,083 restricted stock units @ $0
Disposed/sold 13,527 restricted stock units @ $0
Disposed/sold 1,050 restricted stock units @ $0
Disposed/sold 6,336 restricted stock units @ $0
06/01/2023 4 Hoos Axel (Director) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Disposed/sold 16,800 options to buy @ $0.97, valued at $16.3k
Disposed/sold 9,596 options to buy @ $10.42, valued at $100k
Disposed/sold 12,100 options to buy @ $31.83, valued at $385.1k
Disposed/sold 12,100 options to buy @ $5.21, valued at $63k
06/01/2023 4 Hegde Priti (Director) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Disposed/sold 16,800 options to buy @ $0.97, valued at $16.3k
Disposed/sold 12,100 options to buy @ $5.21, valued at $63k
Disposed/sold 24,968 options to buy @ $16.02, valued at $400k
06/01/2023 4 Gibson Neil W (Director) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Disposed/sold 16,800 options to buy @ $0.97, valued at $16.3k
Disposed/sold 6,270 options to buy @ $16.11, valued at $101k
Disposed/sold 5,000 options to buy @ $16.1, valued at $80.5k
Disposed/sold 12,100 options to buy @ $31.83, valued at $385.1k
Disposed/sold 12,100 options to buy @ $5.21, valued at $63k
Disposed/sold 8,072 options to buy @ $6.07, valued at $49k
06/01/2023 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "FOURTH amended and restated CERTIFICATE OF INCORPORATION OF TCR 2 Therapeutics Inc.",
"SECOND Amended and Restated BY-LAWS OF TCR 2 THERAPEUTICS INC. ARTICLE I OFFICES SECTION 1.1. REGISTERED OFFICE. The registered office of the corporation shall be established and maintained at the office of The Corporation Trust Company, 1209 Orange Street, Corporation Trust Center, Wilmington, Delaware 19801, and said corporation shall be the registered agent of this corporation in charge thereof. SECTION 1.2. OTHER OFFICES. The corporation may have other offices, either within or without the State of Delaware, at such place or places as the board of directors of the corporation may from time to time appoint or the business of the corporation may require. ARTICLE II MEETING OF STOCKHOLDERS SECTION 2.1. PLACE OF MEETINGS. Meetings of the stockholders shall be held at such place, either wit..."
06/01/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
05/30/2023 4 TANG KEVIN C (10% Owner) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Bought 50,000 shares @ $1.72, valued at $86k
05/30/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/24/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/24/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/24/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Assignment of Lease by and between TCR2 Therapeutics Inc. and AstraZeneca Pharmaceuticals LP",
"Lease Modification Agreement by and between TCR2 Therapeutics Inc. and ARE-Maryland No. 31, LLC"
05/24/2023 4 MPM ASSET MANAGEMENT LLC (10% Owner) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Sold 70,170 shares @ $1.88, valued at $131.9k
Exercised (in-or-at-the-money) 42,761 warrants @ $0.74, valued at $31.6k
Exercised (in-or-at-the-money) 135,508 warrants @ $0.74, valued at $100.3k
05/24/2023 4 GADICKE ANSBERT (10% Owner) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Sold 70,170 shares @ $1.88, valued at $131.9k
Exercised (in-or-at-the-money) 42,761 warrants @ $0.74, valued at $31.6k
Exercised (in-or-at-the-money) 135,508 warrants @ $0.74, valued at $100.3k
05/15/2023 4 TANG KEVIN C (10% Owner) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Bought 38,765 shares @ $1.95, valued at $75.6k
Bought 6,183 shares @ $1.95, valued at $12.1k
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "TCR2 Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update CAMBRIDGE, Mass., May 11, 2023 - TCR2 Therapeutics Inc. , a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We are pleased with our continued progress during the last quarter which included the announcement of the strategic combination of TCR2 with Adaptimmune. We believe that the integration of the two companies’ complimentary technology platforms and pipelines focused on treating solid tumors has the potential to fundamentally change the war on cancer,” said Garry Menzel, Ph.D., Presiden..."
05/10/2023 4 TANG KEVIN C (10% Owner) has filed a Form 4 on TCR2 THERAPEUTICS INC.
Txns: Bought 57,073 shares @ $1.95, valued at $111.3k
Bought 20,141 shares @ $1.95, valued at $39.3k
Bought 6,774 shares @ $1.95, valued at $13.2k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy